ABSTRACT -The purpose of our study was to examine the altered gene expression associated with nongenotoxic chemical-mediated liver hypertrophy and successive liver tumor promotion. Five-week-old male rats were fed a basal diet or a diet containing phenobarbital (PB) or clofibrate (CF) for 3 days, 4 weeks, and 13 weeks. Hepatic expression profiling of cell growth-and stress-related genes, as well as those involved in xenobiotic metabolism, was performed by DNA microarray and/or real time quantitative reverse transcription-polymerase chain reaction. The induction of liver hypertrophy and hepatic cytochrome P450 (CYP) isoforms (CYP2B1/2B2 for PB and CYP4A1 for CF) by PB and CF were clearly observed at all the treatment periods examined. Genes encoding DNA damage-inducible 45 (GADD45) family proteins, in particular GADD45g (GADD45 gamma) were down-regulated by treatment with either PB or CF for 4 and 13 weeks. The chemical-mediated development of liver hypertrophy, induction of hepatic CYPs, and suppression of hepatic GADD45g gene at week 13 disappeared at 4 weeks following cessation of the chemical treatment. Additionally, DNA microarray data indicated that cell cycle-related genes such as cyclins CCNB1 and CCNA2 and cyclin-dependent kinase inhibitor CDKN3 were also down-regulated by treatment with either PB or CF at 13 weeks. Since GADD45 functions as a chemical and radiation stress sensor by interacting with cyclins and cyclin-dependent kinase inhibitors, the decrease in the gene expression of GADD45g mRNA observed in this study, may be associated with nongenotoxic chemical-induced tumor promotion of hepatocarcinogenesis rather than liver hypertrophy.
INTRODUCTION
A number of xenobiotics that cause hypertrophy and altered foci in the liver are often reported to induce cytochrome P450s (CYPs) in rodents (Chen and Eaton, 1993; Huang et al., 2005; Deguchi et al., 2009) . Phenobarbital (PB) , an inducer of the CYP2B subfamily enzymes, has been characterized as a typical nongenotoxic carcinogen, which, through its agonistic effect on the constitutive androstane receptor (CAR), causes liver hypertrophy and successive promotion of liver tumors (Feldman et al., 1981; Yamamoto et al., 2004) . Clofibrate (CF), a typical peroxisome proliferator-activated receptor α (PPARα) agonist, is also a nongenotoxic hepatocarcinogen and shows an ability to induce hypertrophy, hyperplasia, and tumor formation in the rodent liver (Holden and Tugwood, 1999; Reddy et al., 1979) . Peroxisome proliferator-mediated activation of PPARα results in induction of various enzymes, including CYP4A1, fatty acid β-oxidation enzyme, acyl-CoA oxidase, apolipoproteins, fatty acid transporters, lipoprotein lipase, and thioesterases (Peters et al., 2005) .
Toxicogenomic studies conducted to identify molecular markers of hepatotoxicity and hepatocarcinogenicity in rodents reveal that hepatotoxicants may be classified into 3 types of chemicals: CYP inducers, hepatocellular necrosis inducers, and hepatocellular cholestasis inducers (Hamadeh et al., 2002a (Hamadeh et al., , 2002b de Longueville et al., 2003; Jessen et al., 2003; Kramer et al., 2004; Elrick et al., 2005; Stierum et al., 2005) . PB and CF are classified as CYP inducer-type hepatotoxicants (de Longueville et al., 2003) ; however, little is known regarding the key molecular events involved in the process of chemicalmediated development of liver hypertrophy and hepatocarcinogenesis. Elrick et al. (2005) reported that PB activates several stress response genes, including growth arrest and DNA damage-inducible 45β gene (GADD45b) in rats. GADD45 was originally identified to be associated with p53 in a radiation-induced DNA damage response (Zhan et al., 1993) ; however, it has since been confirmed that GADD45 family members GADD45α, GADD45β, and GADD45γ interact with cyclins and cyclin-dependent kinase inhibitors, and are implicated in cell cycle arrest as a cellular stress response. Therefore, GADD45α, β, and γ play an important role in the stress signaling pathways controlling cell cycle arrest, DNA repair, cell survival, and/or apoptosis (Liebermann and Hoffman, 2008) .
GADD45α is involved in the DNA repair and survival of damaged cells (Hollander et al., 2001; Gupta et al., 2006) . GADD45β is an antiapoptotic factor, inhibiting c-Jun N-terminal kinase (JNK) signaling in cooperation with NF-κB (Papa et al., 2004 (Papa et al., , 2007 , and GADD45γ inhibits the cell cycle progression from S to G1 phase through interactions with proliferating cell nuclear antigen and p21 (Zhao et al., 2000; Azam et al., 2001 ). Therefore, the next logical step is to examine the expression of GADD45 family members during the process of chemical-mediated development of liver hypertrophy and hepatocarcinogenesis.
In the present study, we administered the CYP inducertype liver hypertrophic chemicals PB and CF to Fischer 344 (F344) rats for 3 days, 4 weeks, and 13 weeks. Subsequent hepatic gene expression profiling of rats treated with PB or CF for 13 weeks revealed down-regulation of some cyclins, cyclin-dependent kinase inhibitors, and GADD45g. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis indicated that liver hypertrophy and induction of CYP(s) (CYP2B1/2B2 for PB and CYP4A1 for CF) resulted from treatment with either PB or CF for all periods examined and, notably, suppression of the GADD45g gene was observed from 4 to 13 weeks after dietary treatment with either chemical.
MATERIALS AND METHODS

Chemicals
PB and CF were purchased from Wako Pure Chemicals Co. Ltd. (Tokyo, Japan). All other chemicals used were of the highest grade available.
Animals and treatments
Sixty male F344 rats (4-week-old), weighing 80 ± 5 g, were purchased from Charles River Co. Ltd. (Tokyo, Japan) and were housed 5 rats per cage with access to tap water and a commercial basal diet (MF; Oriental Yeast Co. Ltd., Tokyo, Japan) during the acclimatization period (one week). During the 1-week acclimatization period, daily clinical signs and body weights were checked. At 5 weeks of age, healthy animals were randomly assigned into 3 groups (20 rats per group) to avoid significant differences of group mean body weights among control (untreated), PB-treated, and CF-treated groups at the beginning of experiment. The rats were fed a basal diet (CRF-1; Oriental Yeast Co. Ltd.) or CRF-1 containing 500 ppm of PB or 2,500 ppm of CF for up to 13 weeks, as illustrated in Figure 1 . Both doses are reported to cause liver neoplasms after long-term treatment (Feldman et al., 1981; Reddy et al., 1979) , and therefore were selected as liver hypertrophy and tumor-inducible doses for this experiment. After 3 days, 4 weeks, and 13 weeks of administration of PB or CF, the livers of 5 rats from each treatment group were excised. At 13 weeks, 5 rats from each treatment group entered a 4-week recovery period, during which they were fed a basal diet (CRF-1), and subsequently, at 17 weeks after the start of the treatment, the livers of the 5 rats were excised. After sacrifice, absolute and relative weights of the liver were measured; the livers were cut into small pieces and stored at -80°C until use. All experiments were performed in accordance with the guidelines for animal experiments set forth by the National Institute of Health Sciences.
Histopathology and morphology
The rat livers from the control and chemical-treated groups were examined for histopathology at day 3, and weeks 4, 13, and 17. After fixation in 10% neutral buff- Vol. 36 No. 5 ered formalin, the livers were embedded in paraffin wax, cut into 3 μm thick sections, routinely processed, and stained with hematoxylin and eosin (H & E).
DNA microarray and RT-PCR analyses
Hepatic gene expression was analyzed by DNA microarray (Agilent Technologies) and qRT-PCR. Total RNA was extracted from a frozen rat liver (approximately 100 mg), using TriPure reagent (Roche) according to the manufacturer's instructions; total concentration and quality of the purified RNA were measured by spectrophotometry. RNA quality was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Tokyo, Japan) as well as ratio between Absorbance unit at 260 nm and that at 280 nm, which should be higher than 1.9.
For DNA microarray analysis, total RNA (500 ng), which comprised total hepatic RNA (100 ng per rat) from 5 individual rats in each experimental group, was labeled with cyanine-3 using a Quick-Amp Labeling Kit (Agilent Technologies). The labeled targets were hybridized to Whole Rat Genome 4x44K oligo DNA microarrays (Agilent Technologies) and hybridized microarrays were scanned using an Agilent Microarray Scanner (Agilent Technologies). Image analysis and raw array data generation were processed using Feature Extraction software (Agilent Technologies). Normalization of the raw array data was performed using Genespring software Ver. 11.
For qRT-PCR analysis, cDNA was prepared from 2 μg of total RNA by reverse transcription using an RT-PCR kit (Invitrogen) according to the manufacturer's instructions.
qRT-PCR with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) was performed using the ABI PRISM 7500 Real-time PCR System (Applied Biosystems) following the manufacturer's protocol supplied with the SYBR Green PCR Master Mix.
The mRNA levels of GADD45a, GADD45b, GADD45g, CYP2B1, CYP2B2, and CYP4A1 were determined, using GAPDH as an internal control. PCR primers were designed using the Primer3Plus software and the primer sequences are listed in Table 1 ; the PCR efficiency for all target genes was almost equal. Target mRNA levels were determined according to the 2 C t method (Livak and Schmittgen, 2001 ). C t values for the specific target gene (C t target ) and GAPDH (C t GAPDH ) were obtained for the chemical-treated and control (chemical-untreated) rats. Assuming these values as C t GAPDH , Using A for chemical-treated group = (C t target C t GAPDH ) treatment . Using B for control group = (C t target C t GAPDH ) control . We took the average (B mean ) of the control group (n = 5) for each target gene and mRNA levels of the target gene relative to the control group were calculated as 2 (A Bmean) . The mRNA levels of each chemical-treated group (n = 5) were expressed as mean (S.D.).
In the present qRT-PCR analysis, we examined differences in Ct values for GAPDH among the untreated, PBand CF-administered study groups. As a result, we did not observe any significant difference in Ct values for GAP-DH. Therefore, GAPDH was considered as an appropriate internal control for the present 2 Ct analysis to evaluate effects of PB and CF on various gene expressions.
Statistical analysis
The data on the body weights, organ weights, and hepatic mRNA levels were expressed as mean (S.D.) (n = 5). Statistically significant difference between the control and chemical-treated groups was evaluated by one-way ANOVA with a post hoc test (Dunnett's test). 
RESULTS
Increases in the absolute and relative liver weights
The chemical treatments did not result in a remarkable decrease in the body weights of rats using the experimental conditions illustrated in Fig. 1 . Changes in the absolute and relative liver weights (g liver weight/100 g body weight) are illustrated in Figs. 2A and B for each treatment period. The absolute liver weights of rats fed 500 ppm PB and 2,500 ppm CF signifi cantly increased at day 3, week 4, and week 13 as compared with controls. Percent increases in PB-fed rats were 25%, 24%, and 35% at day 3, week 4, and week 13, respectively; those in CFfed rats were 24%, 36%, and 31%, respectively. Statistically signifi cant increases in relative liver weights were observed for up to 13 weeks after the PB and CF treatments. Percent increases at day 3, week 4, and week 13 were 24%, 24%, and 33% in PB-treated rats, and 26%, 49%, and 35% in CF-treated rats, respectively. After the 4-week recovery period, the absolute and relative liver weights had returned to those of the control rats.
Histopathology
Representative H & E-stained liver sections of the control and chemical-treated rats are shown in Fig. 3 .
Treatment with PB for 4 weeks resulted in development of centrilobular hypertrophy of hepatocytes (Fig. 3B) , which occurred in a time-dependent manner from day 3 up to week 13. The hepatocytes displayed a ground-glass appearance in their cytoplasm; these histological changes in the liver resulting from PB treatment for 13 weeks disappeared 4 weeks after the cessation of the chemical treatment. The CF-dependent hepatocellular hypertrophy characterized by eosinophilic cytoplasm was also observed at week 4 (Fig. 3C ) and week 13, and the hepatocellular hypertrophy displayed a diffuse distribution throughout the lobules of the liver.
Effects of PB and CF on hepatic gene expression
Altered gene expression in the liver of the rats treated with PB or CF for 13 weeks were initially examined by DNA microarray analyses and revealed changes in gene expression levels, including the GADD45 family genes and the CYP2B/4A subfamily genes, which were further examined by qRT-PCR.
Altered expression of genes related to cell cycle arrest and DNA damage
Changes in the hepatic gene expression profile of genes related to cell cycle arrest and DNA damage were first examined in rats treated with PB and CF for 13 Table 2 . The genes of cyclins (CCNB1andCCNA2), cyclin-dependent kinase inhibitor CDKN3, and GADD45g were down-regulated by both PB and CF treatments. As previously reported (Motojima et al., 1998; Tamura et al., 2006) , the genes LPL, CD36, and LEPR, associated with fatty acid metabolism and energy generation (Holden and Tugwood, 1999) , were up-regulated by both chemical treatments (data not shown).
Since cyclins and cyclin-dependent kinase are known to function as chemical-and radiation-induced stress sensors by interacting with GADD45 proteins, the altered gene expression of hepatic GADD45 family members, GADD45α, GADD45β, and GADD45γ, by PB and CF treatments were further examined by qRT-PCR. 
Altered gene expression of GADD45α
Dietary treatment with PB for 4 and 13 weeks resulted in decreases in levels of hepatic GADD45a mRNA by 43% and 26%, respectively (Fig. 4) . Treatment with CF for 4 and 13 weeks led to signifi cant decreases in the GADD45a mRNA level (by 81% and 59%, respectively). The CF-dependent decrease in GADD45a mRNA level was restored after the 4-week recovery (basal diet) treatment.
Altered gene expression of GADD45β
Expression levels of GADD45b, a CAR-regulated gene (Yamamoto and Negishi, 2008) , at 3 days and 4 weeks after PB treatment were 2.8-fold (P < 0.01) and 4.1-fold (P < 0.001) higher than corresponding controls, respectively (Fig. 5) . In contrast, in CF-treated rats, no such significant increases at day 3 and week 4 were observed, while signifi cant down-regulation of GADD45b occurred at week 13. By DNA microarray analysis, GADD45b was down-regulated at week 13 (0.46-fold of control). After the 4-week recovery (basal diet) period, slight, but significant elevation of GADD45b mRNA level was observed (2.1-fold, P < 0.05).
Altered gene expression of GADD45γ
Statistically significant and persistent down-regulation of GADD45g gene expression by PB and CF was observed at weeks 4 and 13 (Fig. 6) . Treatment with PB for 4 and 13 weeks significantly decreased the level of GADD45g mRNA by 82% and 64%, respectively. Similarly, CF treatment for 4 and 13 weeks decreased the mRNA level by 80% and 85%, respectively. The CFdependent decreases in the level of GADD45g mRNA were restored after the 4-week recovery (basal diet) period. In the case of PB, signifi cant, but rather deviated, elevation in GADD45g mRNA level was detected after the 4-week recovery (basal diet) period.
Altered gene expression of CYP2B1 and CYP2B2
Signifi cant increases in the level of hepatic CYP2B1 mRNA were observed in the rats treated with PB by 82-fold at day 3, 65-fold at week 4, and 26-fold at week 13 (Fig. 7) . The increased level at week 13 returned to the level of the corresponding controls after the 4-week Hepatic GADD45a mRNA levels were measured in rats dosed with 500 ppm phenobarbital or 2,500 ppm clofibrate. GADD45a mRNA levels are shown as a mean (S.D.) for 5 rats from each experimental group. The differences in the GADD45a mRNA levels were compared between the control and the chemical-administered groups for each time point. **, ***Statistically signifi cant differences from the corresponding controls: ** P < 0.01, *** P < 0.001.
Fig. 5. GADD45b mRNA expression in livers of rats administered with phenobarbital (PB) or clofibrate (CF).
Hepatic GADD45b mRNA levels were measured in rats dosed with 500 ppm phenobarbital or 2,500 ppm clofibrate. GADD45b mRNA levels are shown as a mean (S.D.) for 5 rats from each experimental group. The differences in the GADD45b mRNA levels were compared between the control and the chemical-administered groups for each time point. *, **, ***Statistically signifi cant differences from the corresponding controls: * P < 0.05, ** P < 0.01, *** P < 0.001. Fold change represents ratio of hepatic mRNA levels of chemical treated rats to those of control diet-fed rats. Vol. 36 No. 5 recovery (basal diet) treatment. In addition, treatment with PB resulted in an increase in the level of CYP2B2 mRNA: 10.3-fold at day 3, 6.1-fold at week 4, and 8.3-fold at week 13 (data not shown). No signifi cant increases were observed with CF treatment.
Altered gene expression of CYP4A1
Up-regulation of the CYP4A1 gene is reported in male rat livers following exposure to CF (Baker et al., 2004) . Therefore, we examined the effect of dietary CF on expression of CYP4A1, a PPAR-α target gene, and confirmed a significant increase in the level of hepatic CYP4A1 mRNA by CF (Fig. 8) . The CYP4A1 mRNA levels at day 3, week 4, and week 13 were 2.1-, 2.5-, and 2.8-fold higher than the corresponding controls, respectively. No signifi cant increase in the CYP4A1 mRNA level was observed in any PB-treated rats.
DISCUSSION
The ultimate goal of our study was to determine signature gene expression for liver hypertrophy and successive liver tumor promotion induced by nongenotoxic chemicals. Liver hypertrophy developed in rats treated with either PB or CF for 3 days, 4 weeks, and 13 weeks. Similarly, the induction of hepatic CYP2B1/2B2 and CYP4A1 was observed in PB-and CF-treated rats, respectively, for all the treatment periods examined. These chemical-induced increases in liver weight and liver hypertrophy and levels of hepatic CYPs (CYP2B1/2B2 or CYP4A1) were returned to those of the control rats at 4 weeks after the cessation of the chemical treatment. Thus, the nongenotoxic chemicals displayed reversible effects on induction of liver hypertrophy and hepatic CYPs, which is consistent with a known good correlation between the development of liver hypertrophy and the induction of hepatic CYPs, such as PB (CAR activation)-dependent CYP2B induction and CF (PPARα activation)-dependent CYP4A1 induction (Chen and Eaton, 1993; Honkakoski et al., 1998a Honkakoski et al., , 1998b Wei et al., 2000; Sueyoshi and Negishi, 2001; Yoshinari et al., 2001; Yamamoto et al., 2004; Huang et al., 2005) .
Gene expression profi ling in the liver of the rats treated with either PB or CF for 13 weeks revealed the down-regulation of genes associated with cell cycle regulation and DNA damage repair: cyclins CCNB1and CCNA2, cyc- Hepatic GADD45g mRNA levels were measured in rats dosed with 500 ppm phenobarbital or 2,500 ppm clofi brate. GADD45g mRNA levels are shown as mean (S.D.) for 5 rats from each experimental group. The differences in the GADD45g mRNA levels were compared between the control and chemical-administered groups for each time point. *, **, ***Statistically signifi cant differences from the corresponding controls: * P < 0.05, ** P < 0.01, *** P < 0.001. Hepatic CYP2B1 mRNA levels were measured in rats dosed with 500 ppm phenobarbital or 2,500 ppm clofi brate. CYP2B1 mRNA levels are shown as mean (S.D.) for 5 rats from each experimental group. CYP2B1 mRNA levels were compared between the control and the chemical-administered groups for each time point. ***Statistically signifi cant differences from the corresponding controls: *** P < 0.001.
lin-dependent kinase inhibitorCDKN3, and GADD45g. In particular, signifi cant decreases in the expression levels of GADD45g were persistently observed by treatment with either PB or CF for 4 and 13 weeks. It is noteworthy that these chemicals showed different characteristics in terms of the activation of CYP genes (CYP2B1/2B2 and CYP4A1) and their transcription factors (CAR and PPARα). GADD45g has an inhibitory effect on cell cycle progression to adapt to cellular stress (Zhao et al., 2000; Azam et al., 2001; Vairapandi et al., 2002; Togo et al., 2004) , and also functions as a tumor suppressor (Ying et al., 2005) . Genotoxic or cytokine-causing stress was loaded in many studies as variety of "cellular stress" where GADD45g was involved. In contrast, PB and CF are nongenotoxic carcinogens. Thus PB-and CF-mediated suppression of GADD45g gene may be key events that occur during the promotion of hepatocarcinogenesis. No induction of liver cell growth-associated marker (i.e., Ki-67) was observed in rats treated with either chemical for up to 13 weeks (Inoue, Yoshida, Nishikawa, unpublished) , suggesting that the liver tumor-associated cell proliferation may occur after longer-term treatment with nongenotoxic carcinogens. After the 4-week recovery (normal diet) treatment, the elevation of hepatic GADD45g mRNA level was detected in the rats of PB-administered group. Those rats would probably be destined to liver malignancy after longer-term exposure. We currently speculate that repair process from any possible PB-caused toxicity might have started in those rats during the recovery treatment to result in the elevation of GADD45g mRNA level. The elevation varied depending on stochastic PB-damage repair process occurred in the individual animals. Further studies are needed to give an answer to this speculation. Furthermore, in our preliminary experiments, administration of the nongenotoxic hepatocarcinogen piperonyl butoxide (PBO) to rats resulted in a marked decrease in gene expression of GADD45g together with an increase in CYP2B1 expression (Gamou et al., unpublished) . Studies have shown that the hepatocarcinogenicity of PB, CF, and PBO may involve oxidative stress (Elrick et al., 2005; Muguruma et al., 2007; de Longueville et al., 2003) . This reported oxidative stress by PB, CF and PBO, and our present results on the sustained down-regulation of GADD45g may constitute a common cellular stress response pathway. We further consider that the downregulation of Gadd45γ may be associated with the process involved in triggering liver tumor-associated cell growth. Further investigation is needed to prove these hypotheses by investigating influence of oxidative stress and GADD45g expression on liver tumor promotion.
Thus we raise hypothesis that cell growth proliferation toward malignancy might be triggered by or associated with the down-regulation of Gadd45γ. Besides Gadd45γ, down-regulation of Gadd45α and Gadd45β should also be considered with respect to tumor promotion. Downregulation of Gadd45α, which is involved in cell survival in response to DNA damage (Hollander et al., 2001; Liebermann and Hoffman, 2008) , was observed in rats treated with CF for 4 weeks and 13 weeks. GADD45a and GADD45b have also been shown to interact with cdc2-cyclin B1 complex to exert an inhibitory effect on cell cycle progression to adapt cellular stress (Vairapandi et al., 2002) . These findings also raise possibility that down-regulation of Gadd45α has some role in directing hepatocytes to malignancy during the liver tumor promotion process in CF-treated rats. Up-regulation of Gadd45β, which is activated along with CYP2B subfamily genes through activation of CAR by PB (Yamamoto and Negishi, 2008) , occurred in rats treated with PB for 3 days and 4 weeks, but not for 13 weeks. Signifi cant increases in the expression levels of hepatic CYP2B1/2B2 were observed in the rats treated with PB for 13 weeks; however, no significant up-regulation of GADD45b was observed, indicating that up-regulation of Hepatic CYP4A1 mRNA levels were measured in rats dosed with 500 ppm phenobarbital or 2,500 ppm clofi brate. CYP4A1 mRNA levels are shown as mean (S.D.) for 5 rats from each experimental group. CYP4A1 mRNA levels were compared between the control and the chemical-administered groups for each time point. ***Statistically signifi cant differences from the corresponding controls: *** P < 0.001.
GADD45b might not occur solely through activation of CAR. GADD45b might have been down-regulated through currently unknown mechanisms other than CAR around the period of 13 week-administration of PB to return its expressed level to that of untreated rats. We hereby point out a possible role of the Gadd45β down-regulation in liver tumor promotion in rats treated either with PB (cancellation of the observed up-regulation at 4week) or CF (down-regulation) for 13 week, as Vairapandi et al. showed interaction of Gadd45β with cdc2-cyclin B1 complex to exert an inhibitory effect on cell cycle progression (Vairapandi et al., 2002) . Accordingly, the altered gene expression of GADD45a and GADD45b by PB and CF might not necessarily be related to the development of liver hypertrophy. Nor that of GADD45g might be, as GADD45g down-regulation did not occur by treatment with either PB or CF for 3 days.
In conclusion, the present study showed changes in the mRNA levels of the GADD45 gene family members in the livers of rats treated with nongenotoxic chemicals, PB and CF. Decreases in the expression of GADD45g were commonly observed by the treatment with PB and CF for 4 and 13 weeks, and GADD45a and GADD45b were also down-regulated especially after the treatment with CF for 13 weeks, despite that PB and CF show different characteristics in terms of induction of hepatic CYP isoforms. We herein propose that down-regulation of GADD45g and, possibly, GADD45a and GADD45b might be one of the causes of development of liver tumor promotion mediated by some kind of nongenotoxic chemicals rather than liver hypertrophy, which should be elucidated through further study. It is very important to determine what kind of nongenotoxic chemical carcinogens show similar changes in expression of genes including GADD45a, GADD45b, and GADD45g.
